Melasma: a clinical and epidemiological review

Ana Carolina Handel, Luciane Donida Bartoli Miot, Hélio Amante Miot, Ana Carolina Handel, Luciane Donida Bartoli Miot, Hélio Amante Miot

Abstract

Melasma is a chronic acquired hypermelanosis of the skin, characterized by irregular brown macules symmetrically distributed on sun-exposed areas of the body, particularly on the face. It is a common cause of demand for dermatological care that affects mainly women (especially during the menacme), and more pigmented phenotypes (Fitzpatrick skin types III-V). Due to its frequent facial involvement, the disease has an impact on the quality of life of patients. Its pathogeny is not yet completely understood, although there are some known triggering factors such as sun exposure, pregnancy, sexual hormones, inflammatory processes of the skin, use of cosmetics, steroids, and photosensitizing drugs. There is also a clear genetic predisposition, since over 40% of patients reported having relatives affected with the disease. In this manuscript, the authors discuss the main clinical and epidemiological aspects of melasma.

Conflict of interest statement

Conflict of Interest: None.

Figures

FIGURE 1
FIGURE 1
Mixed melasma. Female patient with frontal, temporal, parotid, mandibular, zygomatic, mentonian lesions and lesion in the upper lip
FIGURE 2
FIGURE 2
Extra-facial melasma. Brown pigmentation in the neck area, an area of sun exposure due to the neckline
FIGURE 3
FIGURE 3
Comparison between photography with visible light (top) and with the use of Wood's lamp (bottom) highlighting the limits of the frontal macules of melasma
FIGURE 4
FIGURE 4
Dermoscopy (polarized light) of transitional area: frontal melasma (left) and healthy skin (right). We can observe brown pigment and more intense telangiectasies in the affected area, forming an irregular network

References

    1. Miot LD, Miot HA, Silva MG, Marques ME. Physiopathology of melasma. An Bras Dermatol. 2009;84:623–635.
    1. Corsi H. Chloasma Virginum Periorale. Proc R Soc Med. 1935;28:1169–1169.
    1. Lindsay HC. Chloasma uterinum. Arch Derm Syphilol. 1946;53:58–58.
    1. Bolanca I, Bolanca Z, Kuna K, Vukovic A, Tuckar N, Herman R, et al. Chloasma-the mask of pregnancy. Coll Antropol. 2008;32:139–141.
    1. Plenck JJ. Doctrina de Morbis Cutaneis. Qua hi morbi in suas classes, genera et species redingtur. Vienna, J.F: Van Overbeke; 1776.
    1. Newcomer VD, Lindberg MC, Sternberg TH. A melanosis of the face ("chloasma") Arch Dermatol. 1961;83:284–299.
    1. Lupi O, Nunes S, Gomes Neto A, Pericles C. Doenças dermatológicas no Brasil perfil atitudinal e epidemiológico. An Bras Dermatol. 2010;85:S5–S19.
    1. Sociedade Brasileira de Dermatologia SBD Nosologic profile of dermatologic visits in Brazil. 2006;81:545–554.
    1. Walker SL, Shah M, Hubbard VG, Pradhan HM, Ghimire M. Skin disease is common in rural Nepal: results of a point prevalence study. Br J Dermatol. 2008;158:334–338.
    1. Alakloby OM. Pattern of skin diseases in Eastern Saudi Arabia. Saudi Med J. 2005;26:1607–1610.
    1. Halder RM, Grimes PE, McLaurin CI, Kress MA, Kenney Jr JA. Incidence of common dermatoses in a predominantly black dermatologic practice. Cutis. 1983;32:388–390.
    1. Souza SR, Fischer FM, Souza JM. Suntanning and risk of cutaneous melanoma: a literature review. Rev Saude Publica. 2004;38:588–598.
    1. Taylor SC. Epidemiology of skin diseases in ethnic populations. Dermatol Clin. 2003;21:601–607.
    1. Perez M, Luke J, Rossi A. Melasma in Latin Americans. J Drugs Dermatol. 2011;10:517–523.
    1. Sheth VM, Pandya AG. Melasma a comprehensive update: part I. J Am Acad Dermatol. 2011;65:689–697.
    1. Ishiy PS, Silva LR, Penha MA, Handel AC, Miot HA. Skin diseases reported by workers from the campus of UNESP Rubião Jr, Botucatu-SP (Brazil) An Bras Dermatol. 2014;89:529–531.
    1. Edalatkhah H, Amani F, Rezaifar G. Prevalence of melasma in women in Ardebil city in 2002. Iran J Dermatol. 2004;7:72–77.
    1. Shenoi SD, Davis SV, Rao S, Rao G, Nair S. Dermatoses among paddy field workers--a descriptive, cross-sectional pilot study. Indian J Dermatol Venereol Leprol. 2005;71:254–258.
    1. Scheinfeld NS. Melasma. Skinmed. 2007;6:35–37.
    1. El-Essawi D, Musial JL, Hammad A, Lim HW. A survey of skin disease and skinrelated issues in Arab Americans. J Am Acad Dermatol. 2007;56:933–938.
    1. Werlinger KD, Guevara IL, González CM, Rincón ET, Caetano R, Haley RW, et al. Prevalence of self-diagnosed melasma among premenopausal Latino women in Dallas and Fort Worth, Tex. Arch Dermatol. 2007;143:424–425.
    1. Tamega Ade A, Miot LD, Bonfietti C, Gige TC, Marques ME, Miot HA. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. J Eur Acad Dermatol Venereol. 2013;27:151–156.
    1. Guinot C, Cheffai S, Latreille J, Dhaoui MA, Youssef S, Jaber K, et al. Aggravating factors for melasma: a prospective study in 197 Tunisian patients. J Eur Acad Dermatol Venereol. 2010;24:1060–1069.
    1. Hexsel D, Lacerda DA, Cavalcante AS, Machado Filho CA, Kalil CL, Ayres EL, et al. Epidemiology of melasma in Brazilian patients: a multicenter study. Int J Dermatol. 2013;53:440–444.
    1. Albares Tendero MP, Belinchón Romero I, Ramos Rincón JM, Sánchez Payá J, Costa AL, Pérez Crespo M, et al. Dermatoses in Latin American immigrants seen in a tertiary hospital. Eur J Dermatol. 2009;19:157–162.
    1. Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453–1457.
    1. Kang WH, Yoon KH, Lee ES, Kim J, Lee KB, Yim H, et al. Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol. 2002;146:228–237.
    1. Achar A, Rathi SK. Melasma: a clinico-epidemiological study of 312 cases. Indian J Dermatol. 2011;56:380–382.
    1. Ortonne JP, Arellano I, Berneburg M, Cestari T, Chan H, Grimes P, et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatol Venereol. 2009;23:1254–1262.
    1. Goh CL, Dlova CN. A retrospective study on the clinical presentation and treatment outcome of melasma in a tertiary dermatological referral centre in Singapore. Singapore Med J. 1999;40:455–458.
    1. Pichardo R, Vallejos Q, Feldman SR, Schulz MR, Verma A, Quandt SA, et al. The prevalence of melasma and its association with quality of life in adult male Latino migrant workers. Int J Dermatol. 2009;48:22–26.
    1. Sarkar R, Jain RK, Puri P. Melasma in Indian males. Dermatol Surg. 2003;29:204–204.
    1. Hexsel D, Rodrigues TC, Dal'Forno T, Zechmeister-Prado D, Lima MM. Melasma and pregnancy in southern Brazil. J Eur Acad Dermatol Venereol. 2009;23:367–368.
    1. Wong RC, Ellis CN. Physiologic skin changes in pregnancy. J Am Acad Dermatol. 1984;10:929–940.
    1. Moin A, Jabery Z, Fallah N. Prevalence and awareness of melasma during pregnancy. Int J Dermatol. 2006;45:285–288.
    1. Martin AG, Leal-Khouri S. Physiologic skin changes associated with pregnancy. Int J Dermatol. 1992;31:375–378.
    1. Estève E, Saudeau L, Pierre F, Barruet K, Vaillant L, Lorette G. Physiological cutaneous signs in normal pregnancy: a study of 60 pregnant women. Ann Dermatol Venereol. 1994;121:227–231.
    1. Wade TR, Wade SL, Jones HE. Skin changes and diseases associated with pregnancy. Obstet Gynecol. 1978;52:233–242.
    1. Elling SV, Powell FC. Physiological changes in the skin during pregnancy. Clin Dermatol. 1997;15:35–43.
    1. Wu IB, Lambert C, Lotti TM, Hercogová J, Sintim-Damoa A, Schwartz RA. Melasma. G Ital Dermatol Venereol. 2012;147:413–418.
    1. Resnik S. Melasma induced by oral contraceptive drugs. JAMA. 1967;199:601–605.
    1. Videira IF, Moura DF, Magina S. Mechanisms regulating melanogenesis. An Bras Dermatol. 2013;88:76–83.
    1. Alves GF, Nogueira LSC, Varella TCN. Dermatologia e gestação. An Bras Dermatol. 2005;80:179–186.
    1. Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149:572–577.
    1. Dominguez AR, Balkrishnan R, Ellzey AR, Pandya AG. Melasma in Latina patients: cross-cultural adaptation and validation of a quality-of-life questionnaire in Spanish language. J Am Acad Dermatol. 2006;55:59–66.
    1. Cestari TF, Hexsel D, Viegas ML, Azulay L, Hassun K, Almeida AR, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. Br J Dermatol. 2006;156:13–20.
    1. Misery L, Schmitt AM, Boussetta S, Rahhali N, Taieb C. Melasma: measure of the impact on quality of life using the French version of MELASQOL after cross-cultural adaptation. Acta Derm Venereol. 2010;90:331–332.
    1. Dogramaci AC, Havlucu DY, Inandi T, Balkrishnan R. Validation of a melasma quality of life questionnaire for the Turkish language: the MelasQoL-TR study. J Dermatolog Treat. 2009;20:95–99.
    1. Costa A, Pereira MO, Moisés TA, Cordeiro T, Silva ARD, Amazonas FTP, et al. Avaliação da melhoria na qualidade de vida de portadoras de melasma após uso de combinação botânica à base de Bellis perennis, Glycyrrhiza glabra e Phyllanthus emblica comparado ao da hidroquinona, medido pelo MELASQoL. Surg Cosm Dermatol. 2011;3:207–212.
    1. Purim KS, Avelar MF. Photoprotection, melasma and quality of life in pregnant women. Rev Bras Ginecol Obstet. 2012;34:228–234.
    1. Cestari T, Adjadj L, Hux M, Shimizu MR, Rives VP. Cost-effectiveness of a fixed combination of hydroquinone/tretinoin/fluocinolone cream compared with hydroquinone alone in the treatment of melasma. J Drugs Dermatol. 2007;6:153–160.
    1. Freitag FM, Cestari TF, Leopoldo LR, Paludo P, Boza JC. Effect of melasma on quality of life in a sample of women living in southern Brazil. J Eur Acad Dermatol Venereol. 2008;22:655–662.
    1. Renzi C, Abeni D, Picardi A, Agostini E, Melchi CF, Pasquini P, et al. Factors associated with patient satisfaction with care among dermatological outpatients. Br J Dermatol. 2001;145:617–623.
    1. Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. J Am Acad Dermatol. 2011;65:699–714.
    1. Rendon MI. Utilizing combination therapy to optimize melasma outcomes. J Drugs Dermatol. 2004;3:S27–S34.
    1. Wolf R, Wolf D, Tamir A, Politi Y. Melasma: a mask of stress. Br J Dermatol. 1991;125:192–193.
    1. Victor FC, Gelber J, Rao B. Melasma: a review. J Cutan Med Surg. 2004;8:97–102.
    1. Rigopoulos D, Gregoriou S, Katsambas A. Hyperpigmentation and melasma. J Cosmet Dermatol. 2007;6:195–202.
    1. Katsambas A, Antoniou C. Melasma. Classification and treatment. J Eur Acad Dermatol Venereol. 1995;4:217–223.
    1. Lakhdar H, Zouhair K, Khadir K, Essari A, Richard A, Seité S, et al. Evaluation of the effectiveness of a broad-spectrum sunscreen in the prevention of chloasma in pregnant women. J Eur Acad Dermatol Venereol. 2007;21:738–742.
    1. Miot HA, Miot LD. Re: Topical 10% zinc sulfate solution for treatment of melasma. Dermatol Surg. 2009;35:2050–2051.
    1. Mahmoud BH, Ruvolo E, Hexsel CL, Liu Y, Owen MR, Kollias N, et al. Impact of long-wavelength UVA and visible light on melanocompetent skin. J Invest Dermatol. 2010;130:2092–2097.
    1. Mahmoud BH, Hexsel CL, Hamzavi IH, Lim HW. Effects of visible light on the skin. Photochem Photobiol. 2008;84:450–462.
    1. Adalatkhan H, Amani F. The Correlation between melasma, ovarian cysts and androgenic hormones (a case control study) Res Biol Sci. 2007;2:593–596.
    1. Hassan I, Kaur I, Sialy R, Dash RJ. Hormonal milieu in the maintenance of melasma in fertile women. J Dermatol. 1998;25:510–512.
    1. Mahmood K, Nadeem M, Aman S, Hameed A, Kazmi AH. Role of estrogen, progesterone and prolactin in the etiopathogenesis of melasma in females. J Pak Assoc Dermatol. 2011;21:241–247.
    1. Costin GE, Hearing VJ. Human skin pigmentation: melanocytes modulate skin color in response to stress. FASEB J. 2007;21:976–994.
    1. Scott MC, Suzuki I, Abdel-Malek ZA. Regulation of the human melanocortin 1 receptor expression in epidermal melanocytes by paracrine and endocrine factors and by ultraviolet radiation. Pigment Cell Res. 2002;15:433–439.
    1. Miot LD, Miot HA, Polettini J, Silva MG, Marques ME. Morphologic changes and the expression of alpha-melanocyte stimulating hormone and melanocortin-1 receptor in melasma lesions: a comparative study. Am J Dermatopathol. 2010;32:676–682.
    1. Im S, Lee ES, Kim W, On W, Kim J, Lee M, et al. Donor specific response of estrogen and progesterone on cultured human melanocytes. J Korean Med Sci. 2002;17:58–64.
    1. Kim NH, Cheong KA, Lee TR, Lee AY. PDZK1 upregulation in estrogen-related hyperpigmentation in melasma. J Invest Dermatol. 2012;132:2622–2631.
    1. Ediger TR, Kraus WL, Weinman EJ, Katzenellenbogen BS. Estrogen receptor regulation of the Na+/H+ exchange regulatory factor. Endocrinology. 1999;140:2976–2982.
    1. Stemmer-Rachamimov AO, Wiederhold T, Nielsen GP, James M, Pinney-Michalowski D, Roy JE, et al. NHE-RF, a merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptorpositive breast carcinomas. Am J Pathol. 2001;158:57–62.
    1. Burkhart CG. Chloasma in a man due to oral hormone replacement. Skinmed. 2006;5:46–47.
    1. Sialy R, Hassan I, Kaur I, Dash RJ. Melasma in men: a hormonal profile. J Dermatol. 2000;27:64–65.
    1. Poisson Chloasma in a man with total hypogonadism. Bull Soc Fr Dermatol Syphiligr. 1957;64:777–778.
    1. Pérez M, Sánchez JL, Aguiló F. Endocrinologic profile of patients with idiopathic melasma. J Invest Dermatol. 1983;81:543–545.
    1. Lutfi RJ, Fridmanis M, Misiunas AL, Pafume O, Gonzalez EA, Villemur JA, et al. Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of the melasma. J Clin Endocrinol Metab. 1985;61:28–31.
    1. Yazdanfar A, Hashemi B. Association of Melasma with Thyroid Autoimmunity: A Case-Control Study. Iran J Dermatol. 2010;13:51–53.
    1. Sacre RC, Fernandes NC, Vaisman M, Tendrich M. Melasma idiopático: avaliação das funções tireoidiana, prolactínica e gonadal feminina. An Bras Dermatol. 1996;71:195–198.
    1. Hughes BR. Melasma occurring in twin sisters. J Am Acad Dermatol. 1987;17:841–841.
    1. Dynoodt P, Mestdagh P, Van Peer G, Vandesompele J, Goossens K, Peelman LJ, et al. Identification of miR-145 as a key regulator of the pigmentary process. J Invest Dermatol. 2013;133:201–209.
    1. Kim NH, Lee CH, Lee AY. H19 RNA downregulation stimulated melanogenesis in melasma. Pigment Cell Melanoma Res. 2010;23:84–92.
    1. Passeron T. Melasma pathogenesis and influencing factors - an overview of the latest research. J Eur Acad Dermatol Venereol. 2013;27:5–6.
    1. Kang HY, Suzuki I, Lee DJ, Ha J, Reiniche P, Aubert J, et al. Transcriptional profiling shows altered expression of wnt pathway- and lipid metabolism-related genes as well as melanogenesis-related genes in melasma. J Invest Dermatol. 2011;131:1692–1700.
    1. Lee DJ, Lee J, Ha J, Park KC, Ortonne JP, Kang HY. Defective barrier function in melasma skin. J Eur Acad Dermatol Venereol. 2012;26:1533–1537.
    1. Tomita Y, Maeda K, Tagami H. Melanocyte-stimulating properties of arachidonic acid metabolitespossible role in postinflammatory pigmentation. Pigment Cell Res. 1992;5:357–361.
    1. Negishi K, Kushikata N, Tezuka Y, Takeuchi K, Miyamoto E, Wakamatsu S. Study of the incidence and nature of "very subtle epidermal melasma" in relation to intense pulsed light treatment. Dermatol Surg. 2004;30:881–886.
    1. Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. J Dermatol Sci. 2007;46:111–116.
    1. Pathak MA, Fitzpatrick TB, Kraus EW. Usefulness of retinoic acid in the treatment of melasma. J Am Acad Dermatol. 1986;15:894–899.
    1. Duarte I, Campos Lage AC. Frequency of dermatoses associated with cosmetics. Contact Dermatitis. 2007;56:211–213.
    1. Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, Mihm Jr MC. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol. 1981;4:698–710.
    1. Slominski AT, Botchkarev V, Choudhry M, Fazal N, Fechner K, Furkert J, et al. Cutaneous expression of CRH and CRH-R. Is there a "skin stress response system?". Ann N Y Acad Sci. 1999;885:287–311.
    1. Slominski A, Zbytek B, Semak I, Sweatman T, Wortsman J. CRH stimulates POMC activity and corticosterone production in dermal fibroblasts. J Neuroimmunol. 2005;162:97–102.
    1. Slominski A, Zbytek B, Szczesniewski A, Semak I, Kaminski J, Sweatman T, et al. CRH stimulation of corticosteroids production in melanocytes is mediated by ACTH. Am J Physiol Endocrinol Metab. 2005;288:E701–E706.
    1. Bak H, Lee HJ, Chang SE, Choi JH, Kim MN, Kim BJ. Increased expression of nerve growth factor receptor and neural endopeptidase in the lesional skin of melasma. Dermatol Surg. 2009;35:1244–1250.
    1. Adalatkhah H, Sadeghi-bazargani H, Amini-sani N, Zeynizadeh S. Melasma and its association with different types of nevi in women: A case-control study. BMC Dermatol. 2008;8:3–3.
    1. Adalatkhah H, Sadeghi Bazargani H. The association between melasma and postinflammatory hyperpigmentation in acne patients. Iran Red Crescent Med J. 2013;15:400–403.
    1. Mandry Pagan R, Sanchez JL. Mandibular melasma. P R Health Sci J. 2000;19:231–234.
    1. Diffey BL, Tate TJ, Davis A. Solar dosimetry of the face: the relationship of natural ultraviolet radiation exposure to basal cell carcinoma localisation. Phys Med Biol. 1979;24:931–939.
    1. Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006;55:1048–1065.
    1. Ritter CG, Fiss DV, Borges da Costa JA, de Carvalho RR, Bauermann G, Cestari TF. Extra-facial melasma: clinical, histopathological, and immunohistochemical casecontrol study. J Eur Acad Dermatol Venereol. 2013:271088–271094.
    1. O'Brien TJ, Dyall-Smith D, Hall AP. Melasma of the arms associated with hormone replacement therapy. Br J Dermatol. 1999;141:592–593.
    1. O'Brien TJ, Dyall-Smith D, Hall AP. Melasma of the forearms. Australas J Dermatol. 1997;38:35–37.
    1. Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2000;18:91-8,ix.
    1. Pandya A, Berneburg M, Ortonne JP, Picardo M. Guidelines for clinical trials in melasma. Pigmentation Disorders Academy. Br J Dermatol. 2006;156:21–28.
    1. Al-Aboosi M, Abalkhail A, Kasim O, Al-Khatib A, Qarqaz F, Todd D, et al. Friction melanosis: a clinical, histologic, and ultrastructural study in Jordanian patients. Int J Dermatol. 2004;43:261–264.
    1. Al-Samary A, Al Mohizea S, Bin-Saif G, Al-Balbeesi A. Pigmentary demarcation lines on the face in Saudi women. Indian J Dermatol Venereol Leprol. 2010;76:378–381.
    1. James WD, Carter JM, Rodman OG. Pigmentary demarcation lines: a population survey. J Am Acad Dermatol. 1987;16:584–590.
    1. Ponzio HA, Cruz M. Acurácia do exame sob a lâmpada de Wood na classificação dos cloasmas. An Bras Dermatol. 1993;68:325–328.
    1. Barcauí CB, Pereira FBC, Tamler C, Fonseca RMR. Classificação do melasma pela dermatoscopia: estudo comparativo com lâmpada de Wood. Surg Cosm Dermatol. 2009;1:115–119.
    1. Kang HY, Bahadoran P, Suzuki I, Zugaj D, Khemis A, Passeron T, et al. In vivo reflectance confocal microscopy detects pigmentary changes in melasma at a cellular level resolution. Exp Dermatol. 2010;19:e228–e233.
    1. Kang HY, Bahadoran P. Application of in vivo reflectance confocal microscopy in melasma classification. J Am Acad Dermatol. 2012;67:157–157.
    1. Ardigo M, Cameli N, Berardesca E, Gonzalez S. Characterization and evaluation of pigment distribution and response to therapy in melasma using in vivo reflectance confocal microscopy: a preliminary study. J Eur Acad Dermatol Venereol. 2010;24:1296–1303.
    1. Costa MC, Eljaiek HV, Abraham LS, Azulay-Abulafia L, Ardigo M. In vivo reflectance confocal microscopy in a typical case of melasma. An Bras Dermatol. 2012;87:782–784.
    1. Kimbrough-Green CK, Griffiths CE, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, Ellis CN, et al. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch Dermatol. 1994;130:727–733.
    1. Taylor S, Westerhof W, Im S, Lim J. Noninvasive techniques for the evaluation of skin color. J Am Acad Dermatol. 2006;54:S282–S290.
    1. Pratchyapruit W, Vashrangsi N, Sindhavananda J, Tagami H. Instrumental analysis of the pattern of improvement and that of recurrence of melasma in Thai females treated with Kligman-Willis triple combination therapy: confirmation by using its two different formulae. Skin Res Technol. 2011;17:226–233.
    1. Pandya AG, Hynan LS, Bhore R, Riley FC, Guevara IL, Grimes P, et al. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2011;64:78–83. 78-83,83.e1-2.
    1. Hernández-Barrera R, Torres-Alvarez B, Castanedo-Cazares JP, Oros-Ovalle C, Moncada B. Solar elastosis and presence of mast cells as key features in the pathogenesis of melasma. Clin Exp Dermatol. 2008;33:305–308.
    1. Jang YH, Lee JY, Kang HY, Lee ES, Kim YC. Oestrogen and progesterone receptor expression in melasma: an immunohistochemical analysis. J Eur Acad Dermatol Venereol. 2010;24:1312–1316.
    1. Im S, Kim J, On WY, Kang WH. Increased expression of alpha-melanocyte-stimulating hormone in the lesional skin of melasma. Br J Dermatol. 2002;146:165–167.
    1. Damoa AS, Lambert W, Schwartz R. Melasma: Insight into a distressing dyschromia. Aesthet Dermatol. 2006;8:1–6.
    1. Sardesai VR, Kolte JN, Srinivas BN. A clinical study of melasma and a comparison of the therapeutic effect of certain currently available topical modalities for its treatment. Indian J Dermatol. 2013;58:239–239.
    1. Ball Arefiev KL, Hantash BM. Advances in the treatment of melasma: a review of the recent literature. Dermatol Surg. 2012;38:971–984.
    1. Rajaratnam R, Halpern J, Salim A, Emmett C. Interventions for melasma. Cochrane Database Syst Rev. 2010:

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다